Indeed, in a very similar experimental setting (with IL‐2 produced by anti‐CD3/anti‐CD28 stimulated PBMCs), we could accurately identify latent Tregs in SLE patients and could demonstrate a clear difference between ISG15lo and ISG15hi patients in terms of Treg percentage. The gene discussed is IL2; the disease is systemic lupus erythematosus.